nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezogabine—CYP2A6—Arformoterol—chronic obstructive pulmonary disease	0.202	0.312	CbGbCtD
Ezogabine—CYP2A6—Formoterol—chronic obstructive pulmonary disease	0.202	0.312	CbGbCtD
Ezogabine—CYP2A6—Montelukast—chronic obstructive pulmonary disease	0.153	0.237	CbGbCtD
Ezogabine—CYP2A6—Prednisolone—chronic obstructive pulmonary disease	0.0897	0.139	CbGbCtD
Ezogabine—Suicidal behaviour—Montelukast—chronic obstructive pulmonary disease	0.00705	0.0346	CcSEcCtD
Ezogabine—Psychiatric symptom—Prednisone—chronic obstructive pulmonary disease	0.00621	0.0305	CcSEcCtD
Ezogabine—Hypokinesia—Formoterol—chronic obstructive pulmonary disease	0.00269	0.0132	CcSEcCtD
Ezogabine—Hypokinesia—Arformoterol—chronic obstructive pulmonary disease	0.00269	0.0132	CcSEcCtD
Ezogabine—Memory impairment—Montelukast—chronic obstructive pulmonary disease	0.00227	0.0111	CcSEcCtD
Ezogabine—Nephrolithiasis—Arformoterol—chronic obstructive pulmonary disease	0.00226	0.0111	CcSEcCtD
Ezogabine—Nephrolithiasis—Formoterol—chronic obstructive pulmonary disease	0.00226	0.0111	CcSEcCtD
Ezogabine—Influenza—Roflumilast—chronic obstructive pulmonary disease	0.00225	0.011	CcSEcCtD
Ezogabine—Coma—Aminophylline—chronic obstructive pulmonary disease	0.00218	0.0107	CcSEcCtD
Ezogabine—Disturbance in attention—Montelukast—chronic obstructive pulmonary disease	0.00206	0.0101	CcSEcCtD
Ezogabine—Skin discolouration—Arformoterol—chronic obstructive pulmonary disease	0.00201	0.00989	CcSEcCtD
Ezogabine—Skin discolouration—Formoterol—chronic obstructive pulmonary disease	0.00201	0.00989	CcSEcCtD
Ezogabine—Infestation NOS—Roflumilast—chronic obstructive pulmonary disease	0.002	0.00985	CcSEcCtD
Ezogabine—Infestation—Roflumilast—chronic obstructive pulmonary disease	0.002	0.00985	CcSEcCtD
Ezogabine—Disorientation—Aminophylline—chronic obstructive pulmonary disease	0.00194	0.00952	CcSEcCtD
Ezogabine—Hepatobiliary disease—Roflumilast—chronic obstructive pulmonary disease	0.0019	0.00931	CcSEcCtD
Ezogabine—Urinary retention—Aminophylline—chronic obstructive pulmonary disease	0.00165	0.0081	CcSEcCtD
Ezogabine—Mental disorder—Roflumilast—chronic obstructive pulmonary disease	0.00158	0.00774	CcSEcCtD
Ezogabine—Malnutrition—Roflumilast—chronic obstructive pulmonary disease	0.00157	0.00769	CcSEcCtD
Ezogabine—Urinary retention—Tiotropium—chronic obstructive pulmonary disease	0.00155	0.00764	CcSEcCtD
Ezogabine—Muscle spasms—Roflumilast—chronic obstructive pulmonary disease	0.00151	0.0074	CcSEcCtD
Ezogabine—Euphoric mood—Salbutamol—chronic obstructive pulmonary disease	0.00147	0.00725	CcSEcCtD
Ezogabine—Tremor—Roflumilast—chronic obstructive pulmonary disease	0.00147	0.00721	CcSEcCtD
Ezogabine—Ill-defined disorder—Roflumilast—chronic obstructive pulmonary disease	0.00145	0.00714	CcSEcCtD
Ezogabine—Disorientation—Montelukast—chronic obstructive pulmonary disease	0.00144	0.0071	CcSEcCtD
Ezogabine—Dysphagia—Tiotropium—chronic obstructive pulmonary disease	0.00141	0.00694	CcSEcCtD
Ezogabine—Malaise—Roflumilast—chronic obstructive pulmonary disease	0.00141	0.00694	CcSEcCtD
Ezogabine—Vertigo—Roflumilast—chronic obstructive pulmonary disease	0.00141	0.00691	CcSEcCtD
Ezogabine—Anxiety—Roflumilast—chronic obstructive pulmonary disease	0.00133	0.00653	CcSEcCtD
Ezogabine—Increased appetite—Salbutamol—chronic obstructive pulmonary disease	0.00133	0.00652	CcSEcCtD
Ezogabine—Dysuria—Tiotropium—chronic obstructive pulmonary disease	0.00132	0.00649	CcSEcCtD
Ezogabine—Discomfort—Roflumilast—chronic obstructive pulmonary disease	0.00132	0.00647	CcSEcCtD
Ezogabine—Haematuria—Aminophylline—chronic obstructive pulmonary disease	0.00127	0.00626	CcSEcCtD
Ezogabine—Infection—Roflumilast—chronic obstructive pulmonary disease	0.00127	0.00624	CcSEcCtD
Ezogabine—Nervous system disorder—Roflumilast—chronic obstructive pulmonary disease	0.00125	0.00616	CcSEcCtD
Ezogabine—Influenza—Arformoterol—chronic obstructive pulmonary disease	0.00114	0.0056	CcSEcCtD
Ezogabine—Influenza—Formoterol—chronic obstructive pulmonary disease	0.00114	0.0056	CcSEcCtD
Ezogabine—Dyspepsia—Roflumilast—chronic obstructive pulmonary disease	0.00112	0.00553	CcSEcCtD
Ezogabine—Influenza—Montelukast—chronic obstructive pulmonary disease	0.00112	0.00549	CcSEcCtD
Ezogabine—Urinary tract disorder—Tiotropium—chronic obstructive pulmonary disease	0.00112	0.00549	CcSEcCtD
Ezogabine—Oedema peripheral—Tiotropium—chronic obstructive pulmonary disease	0.00111	0.00548	CcSEcCtD
Ezogabine—Urethral disorder—Tiotropium—chronic obstructive pulmonary disease	0.00111	0.00545	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.0011	0.00542	CcSEcCtD
Ezogabine—Fatigue—Roflumilast—chronic obstructive pulmonary disease	0.0011	0.00541	CcSEcCtD
Ezogabine—Constipation—Roflumilast—chronic obstructive pulmonary disease	0.00109	0.00537	CcSEcCtD
Ezogabine—Visual impairment—Tiotropium—chronic obstructive pulmonary disease	0.00109	0.00536	CcSEcCtD
Ezogabine—Influenza—Salbutamol—chronic obstructive pulmonary disease	0.00108	0.00529	CcSEcCtD
Ezogabine—Alopecia—Aminophylline—chronic obstructive pulmonary disease	0.00106	0.00521	CcSEcCtD
Ezogabine—Eye disorder—Tiotropium—chronic obstructive pulmonary disease	0.00106	0.00519	CcSEcCtD
Ezogabine—Feeling abnormal—Roflumilast—chronic obstructive pulmonary disease	0.00105	0.00517	CcSEcCtD
Ezogabine—Dysuria—Salbutamol—chronic obstructive pulmonary disease	0.00101	0.00495	CcSEcCtD
Ezogabine—Infestation NOS—Montelukast—chronic obstructive pulmonary disease	0.000996	0.00489	CcSEcCtD
Ezogabine—Infestation—Montelukast—chronic obstructive pulmonary disease	0.000996	0.00489	CcSEcCtD
Ezogabine—Mental disorder—Tiotropium—chronic obstructive pulmonary disease	0.000991	0.00487	CcSEcCtD
Ezogabine—Malnutrition—Tiotropium—chronic obstructive pulmonary disease	0.000985	0.00484	CcSEcCtD
Ezogabine—Tremor—Aminophylline—chronic obstructive pulmonary disease	0.000978	0.00481	CcSEcCtD
Ezogabine—Haematuria—Formoterol—chronic obstructive pulmonary disease	0.00097	0.00476	CcSEcCtD
Ezogabine—Haematuria—Arformoterol—chronic obstructive pulmonary disease	0.00097	0.00476	CcSEcCtD
Ezogabine—Hepatobiliary disease—Montelukast—chronic obstructive pulmonary disease	0.000942	0.00463	CcSEcCtD
Ezogabine—Vision blurred—Tiotropium—chronic obstructive pulmonary disease	0.000928	0.00456	CcSEcCtD
Ezogabine—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.000917	0.00451	CcSEcCtD
Ezogabine—Haematuria—Salbutamol—chronic obstructive pulmonary disease	0.000916	0.0045	CcSEcCtD
Ezogabine—Memory impairment—Prednisone—chronic obstructive pulmonary disease	0.000912	0.00448	CcSEcCtD
Ezogabine—Urinary tract disorder—Formoterol—chronic obstructive pulmonary disease	0.000902	0.00443	CcSEcCtD
Ezogabine—Urinary tract disorder—Arformoterol—chronic obstructive pulmonary disease	0.000902	0.00443	CcSEcCtD
Ezogabine—Oedema peripheral—Formoterol—chronic obstructive pulmonary disease	0.000899	0.00442	CcSEcCtD
Ezogabine—Oedema peripheral—Arformoterol—chronic obstructive pulmonary disease	0.000899	0.00442	CcSEcCtD
Ezogabine—Urethral disorder—Formoterol—chronic obstructive pulmonary disease	0.000895	0.0044	CcSEcCtD
Ezogabine—Urethral disorder—Arformoterol—chronic obstructive pulmonary disease	0.000895	0.0044	CcSEcCtD
Ezogabine—Hallucination—Montelukast—chronic obstructive pulmonary disease	0.00089	0.00437	CcSEcCtD
Ezogabine—Anxiety—Aminophylline—chronic obstructive pulmonary disease	0.000886	0.00435	CcSEcCtD
Ezogabine—Syncope—Tiotropium—chronic obstructive pulmonary disease	0.000883	0.00434	CcSEcCtD
Ezogabine—Urinary tract disorder—Montelukast—chronic obstructive pulmonary disease	0.000883	0.00434	CcSEcCtD
Ezogabine—Visual impairment—Formoterol—chronic obstructive pulmonary disease	0.00088	0.00432	CcSEcCtD
Ezogabine—Visual impairment—Arformoterol—chronic obstructive pulmonary disease	0.00088	0.00432	CcSEcCtD
Ezogabine—Urethral disorder—Montelukast—chronic obstructive pulmonary disease	0.000877	0.00431	CcSEcCtD
Ezogabine—Loss of consciousness—Tiotropium—chronic obstructive pulmonary disease	0.000866	0.00425	CcSEcCtD
Ezogabine—Urinary tract disorder—Salbutamol—chronic obstructive pulmonary disease	0.000851	0.00418	CcSEcCtD
Ezogabine—Infection—Aminophylline—chronic obstructive pulmonary disease	0.000847	0.00416	CcSEcCtD
Ezogabine—Euphoric mood—Prednisolone—chronic obstructive pulmonary disease	0.000846	0.00416	CcSEcCtD
Ezogabine—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.000845	0.00415	CcSEcCtD
Ezogabine—Urethral disorder—Salbutamol—chronic obstructive pulmonary disease	0.000845	0.00415	CcSEcCtD
Ezogabine—Shock—Aminophylline—chronic obstructive pulmonary disease	0.000838	0.00412	CcSEcCtD
Ezogabine—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.000836	0.00411	CcSEcCtD
Ezogabine—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.00082	0.00403	CcSEcCtD
Ezogabine—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000806	0.00396	CcSEcCtD
Ezogabine—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000805	0.00396	CcSEcCtD
Ezogabine—Mental disorder—Formoterol—chronic obstructive pulmonary disease	0.0008	0.00393	CcSEcCtD
Ezogabine—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	0.0008	0.00393	CcSEcCtD
Ezogabine—Infection—Tiotropium—chronic obstructive pulmonary disease	0.000798	0.00392	CcSEcCtD
Ezogabine—Malnutrition—Arformoterol—chronic obstructive pulmonary disease	0.000795	0.0039	CcSEcCtD
Ezogabine—Malnutrition—Formoterol—chronic obstructive pulmonary disease	0.000795	0.0039	CcSEcCtD
Ezogabine—Shock—Tiotropium—chronic obstructive pulmonary disease	0.000791	0.00389	CcSEcCtD
Ezogabine—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.000788	0.00387	CcSEcCtD
Ezogabine—Mental disorder—Montelukast—chronic obstructive pulmonary disease	0.000783	0.00385	CcSEcCtD
Ezogabine—Muscle spasms—Arformoterol—chronic obstructive pulmonary disease	0.000764	0.00375	CcSEcCtD
Ezogabine—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	0.000764	0.00375	CcSEcCtD
Ezogabine—Increased appetite—Prednisolone—chronic obstructive pulmonary disease	0.000761	0.00374	CcSEcCtD
Ezogabine—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000759	0.00373	CcSEcCtD
Ezogabine—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.000755	0.00371	CcSEcCtD
Ezogabine—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.00075	0.00369	CcSEcCtD
Ezogabine—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.00075	0.00369	CcSEcCtD
Ezogabine—Muscle spasms—Montelukast—chronic obstructive pulmonary disease	0.000748	0.00368	CcSEcCtD
Ezogabine—Tremor—Formoterol—chronic obstructive pulmonary disease	0.000745	0.00366	CcSEcCtD
Ezogabine—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.000745	0.00366	CcSEcCtD
Ezogabine—Ill-defined disorder—Arformoterol—chronic obstructive pulmonary disease	0.000737	0.00362	CcSEcCtD
Ezogabine—Ill-defined disorder—Formoterol—chronic obstructive pulmonary disease	0.000737	0.00362	CcSEcCtD
Ezogabine—Tremor—Montelukast—chronic obstructive pulmonary disease	0.000729	0.00358	CcSEcCtD
Ezogabine—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000722	0.00355	CcSEcCtD
Ezogabine—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.000721	0.00354	CcSEcCtD
Ezogabine—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.000717	0.00352	CcSEcCtD
Ezogabine—Malaise—Formoterol—chronic obstructive pulmonary disease	0.000717	0.00352	CcSEcCtD
Ezogabine—Osteoarthritis—Prednisolone—chronic obstructive pulmonary disease	0.000715	0.00351	CcSEcCtD
Ezogabine—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000707	0.00348	CcSEcCtD
Ezogabine—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000703	0.00345	CcSEcCtD
Ezogabine—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.000696	0.00342	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000694	0.00341	CcSEcCtD
Ezogabine—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000687	0.00338	CcSEcCtD
Ezogabine—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.000677	0.00333	CcSEcCtD
Ezogabine—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000674	0.00331	CcSEcCtD
Ezogabine—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000674	0.00331	CcSEcCtD
Ezogabine—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.000674	0.00331	CcSEcCtD
Ezogabine—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000673	0.00331	CcSEcCtD
Ezogabine—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000668	0.00328	CcSEcCtD
Ezogabine—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000668	0.00328	CcSEcCtD
Ezogabine—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000662	0.00325	CcSEcCtD
Ezogabine—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000662	0.00325	CcSEcCtD
Ezogabine—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.00066	0.00325	CcSEcCtD
Ezogabine—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.00066	0.00324	CcSEcCtD
Ezogabine—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000644	0.00317	CcSEcCtD
Ezogabine—Infection—Formoterol—chronic obstructive pulmonary disease	0.000644	0.00317	CcSEcCtD
Ezogabine—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000637	0.00313	CcSEcCtD
Ezogabine—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000636	0.00313	CcSEcCtD
Ezogabine—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000636	0.00313	CcSEcCtD
Ezogabine—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000631	0.0031	CcSEcCtD
Ezogabine—Infection—Montelukast—chronic obstructive pulmonary disease	0.000631	0.0031	CcSEcCtD
Ezogabine—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000625	0.00307	CcSEcCtD
Ezogabine—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000623	0.00306	CcSEcCtD
Ezogabine—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000622	0.00306	CcSEcCtD
Ezogabine—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	0.000615	0.00302	CcSEcCtD
Ezogabine—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000608	0.00299	CcSEcCtD
Ezogabine—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000603	0.00296	CcSEcCtD
Ezogabine—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000601	0.00295	CcSEcCtD
Ezogabine—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000592	0.00291	CcSEcCtD
Ezogabine—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000578	0.00284	CcSEcCtD
Ezogabine—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000578	0.00284	CcSEcCtD
Ezogabine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000577	0.00283	CcSEcCtD
Ezogabine—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000577	0.00283	CcSEcCtD
Ezogabine—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000571	0.00281	CcSEcCtD
Ezogabine—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000571	0.00281	CcSEcCtD
Ezogabine—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.00057	0.0028	CcSEcCtD
Ezogabine—UGT1A4—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000566	0.00376	CbGpPWpGaD
Ezogabine—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000565	0.00278	CcSEcCtD
Ezogabine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000564	0.00277	CcSEcCtD
Ezogabine—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000562	0.00276	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00056	0.00275	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00056	0.00275	CcSEcCtD
Ezogabine—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000559	0.00275	CcSEcCtD
Ezogabine—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000559	0.00275	CcSEcCtD
Ezogabine—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000559	0.00275	CcSEcCtD
Ezogabine—NAT2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000557	0.0037	CbGpPWpGaD
Ezogabine—UGT1A4—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	0.000555	0.00368	CbGpPWpGaD
Ezogabine—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000555	0.00273	CcSEcCtD
Ezogabine—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000555	0.00273	CcSEcCtD
Ezogabine—Increased appetite—Prednisone—chronic obstructive pulmonary disease	0.000553	0.00272	CcSEcCtD
Ezogabine—Amnesia—Prednisone—chronic obstructive pulmonary disease	0.000553	0.00272	CcSEcCtD
Ezogabine—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.00055	0.0027	CcSEcCtD
Ezogabine—NAT2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.00055	0.00364	CbGpPWpGaD
Ezogabine—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000548	0.00269	CcSEcCtD
Ezogabine—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000548	0.00269	CcSEcCtD
Ezogabine—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000546	0.00268	CcSEcCtD
Ezogabine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000544	0.00268	CcSEcCtD
Ezogabine—UGT1A3—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	0.000543	0.0036	CbGpPWpGaD
Ezogabine—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000539	0.00265	CcSEcCtD
Ezogabine—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000537	0.00264	CcSEcCtD
Ezogabine—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000537	0.00264	CcSEcCtD
Ezogabine—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000534	0.00263	CcSEcCtD
Ezogabine—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000534	0.00263	CcSEcCtD
Ezogabine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000531	0.00261	CcSEcCtD
Ezogabine—UGT1A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.00053	0.00352	CbGpPWpGaD
Ezogabine—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000529	0.0026	CcSEcCtD
Ezogabine—NAT2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000528	0.0035	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	0.000528	0.0035	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	0.000528	0.0035	CbGpPWpGaD
Ezogabine—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000528	0.00259	CcSEcCtD
Ezogabine—UGT1A1—NRF2 pathway—SOD3—chronic obstructive pulmonary disease	0.000527	0.00349	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—SOD3—chronic obstructive pulmonary disease	0.000527	0.00349	CbGpPWpGaD
Ezogabine—UGT1A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000524	0.00347	CbGpPWpGaD
Ezogabine—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000524	0.00257	CcSEcCtD
Ezogabine—UGT1A3—Phase II conjugation—GSTP1—chronic obstructive pulmonary disease	0.000522	0.00346	CbGpPWpGaD
Ezogabine—NAT2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.000521	0.00346	CbGpPWpGaD
Ezogabine—UGT1A1—Phase II conjugation—GSTT1—chronic obstructive pulmonary disease	0.00052	0.00345	CbGpPWpGaD
Ezogabine—UGT1A9—Phase II conjugation—GSTT1—chronic obstructive pulmonary disease	0.00052	0.00345	CbGpPWpGaD
Ezogabine—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.000519	0.00255	CcSEcCtD
Ezogabine—UGT1A9—Phase II conjugation—GCLC—chronic obstructive pulmonary disease	0.000514	0.00341	CbGpPWpGaD
Ezogabine—UGT1A1—Phase II conjugation—GCLC—chronic obstructive pulmonary disease	0.000514	0.00341	CbGpPWpGaD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	0.000509	0.00337	CbGpPWpGaD
Ezogabine—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	0.000507	0.00249	CcSEcCtD
Ezogabine—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000507	0.00249	CcSEcCtD
Ezogabine—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000506	0.00249	CcSEcCtD
Ezogabine—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000506	0.00249	CcSEcCtD
Ezogabine—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000505	0.00248	CcSEcCtD
Ezogabine—UGT1A3—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000497	0.00329	CbGpPWpGaD
Ezogabine—UGT1A3—Phase II conjugation—GSTM1—chronic obstructive pulmonary disease	0.00048	0.00318	CbGpPWpGaD
Ezogabine—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000477	0.00235	CcSEcCtD
Ezogabine—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000476	0.00234	CcSEcCtD
Ezogabine—UGT1A3—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000471	0.00312	CbGpPWpGaD
Ezogabine—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000465	0.00229	CcSEcCtD
Ezogabine—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000465	0.00229	CcSEcCtD
Ezogabine—UGT1A3—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	0.000462	0.00306	CbGpPWpGaD
Ezogabine—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000456	0.00224	CcSEcCtD
Ezogabine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000453	0.003	CbGpPWpGaD
Ezogabine—CYP2A6—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000447	0.00296	CbGpPWpGaD
Ezogabine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—chronic obstructive pulmonary disease	0.000444	0.00294	CbGpPWpGaD
Ezogabine—UGT1A3—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000441	0.00292	CbGpPWpGaD
Ezogabine—UGT1A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000441	0.00292	CbGpPWpGaD
Ezogabine—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000439	0.00216	CcSEcCtD
Ezogabine—UGT1A3—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000436	0.00289	CbGpPWpGaD
Ezogabine—UGT1A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000435	0.00288	CbGpPWpGaD
Ezogabine—UGT1A1—Phase II conjugation—CYP1A2—chronic obstructive pulmonary disease	0.000433	0.00287	CbGpPWpGaD
Ezogabine—UGT1A9—Phase II conjugation—CYP1A2—chronic obstructive pulmonary disease	0.000433	0.00287	CbGpPWpGaD
Ezogabine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000429	0.00211	CcSEcCtD
Ezogabine—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000429	0.00211	CcSEcCtD
Ezogabine—NAT2—Metabolism—APIP—chronic obstructive pulmonary disease	0.000425	0.00282	CbGpPWpGaD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	0.000423	0.0028	CbGpPWpGaD
Ezogabine—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.00042	0.00206	CcSEcCtD
Ezogabine—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.00042	0.00206	CcSEcCtD
Ezogabine—UGT1A4—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	0.000419	0.00278	CbGpPWpGaD
Ezogabine—UGT1A4—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	0.000413	0.00274	CbGpPWpGaD
Ezogabine—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000409	0.00201	CcSEcCtD
Ezogabine—Rash—Formoterol—chronic obstructive pulmonary disease	0.000409	0.00201	CcSEcCtD
Ezogabine—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000409	0.00201	CcSEcCtD
Ezogabine—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000409	0.00201	CcSEcCtD
Ezogabine—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.000409	0.00201	CcSEcCtD
Ezogabine—CYP2A6—NRF2 pathway—SOD3—chronic obstructive pulmonary disease	0.000406	0.00269	CbGpPWpGaD
Ezogabine—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000406	0.00199	CcSEcCtD
Ezogabine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000405	0.00199	CcSEcCtD
Ezogabine—Rash—Montelukast—chronic obstructive pulmonary disease	0.000401	0.00197	CcSEcCtD
Ezogabine—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.0004	0.00197	CcSEcCtD
Ezogabine—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000399	0.00196	CcSEcCtD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	0.000395	0.00262	CbGpPWpGaD
Ezogabine—UGT1A9—PPARA activates gene expression—CTGF—chronic obstructive pulmonary disease	0.000393	0.0026	CbGpPWpGaD
Ezogabine—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000388	0.00191	CcSEcCtD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	0.000388	0.00257	CbGpPWpGaD
Ezogabine—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000387	0.0019	CcSEcCtD
Ezogabine—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000386	0.0019	CcSEcCtD
Ezogabine—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000386	0.0019	CcSEcCtD
Ezogabine—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000386	0.0019	CcSEcCtD
Ezogabine—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000385	0.00189	CcSEcCtD
Ezogabine—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000385	0.00189	CcSEcCtD
Ezogabine—UGT1A4—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	0.000385	0.00255	CbGpPWpGaD
Ezogabine—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CTGF—chronic obstructive pulmonary disease	0.000384	0.00255	CbGpPWpGaD
Ezogabine—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000378	0.00186	CcSEcCtD
Ezogabine—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000377	0.00185	CcSEcCtD
Ezogabine—UGT1A1—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	0.000375	0.00249	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	0.000375	0.00249	CbGpPWpGaD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	0.000369	0.00245	CbGpPWpGaD
Ezogabine—UGT1A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000367	0.00244	CbGpPWpGaD
Ezogabine—CYP2A6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000367	0.00243	CbGpPWpGaD
Ezogabine—UGT1A3—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000366	0.00243	CbGpPWpGaD
Ezogabine—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000364	0.00179	CcSEcCtD
Ezogabine—UGT1A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000362	0.0024	CbGpPWpGaD
Ezogabine—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000362	0.00178	CcSEcCtD
Ezogabine—UGT1A3—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000361	0.0024	CbGpPWpGaD
Ezogabine—UGT1A1—Phase II conjugation—GSTP1—chronic obstructive pulmonary disease	0.000361	0.00239	CbGpPWpGaD
Ezogabine—UGT1A9—Phase II conjugation—GSTP1—chronic obstructive pulmonary disease	0.000361	0.00239	CbGpPWpGaD
Ezogabine—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.000357	0.00176	CcSEcCtD
Ezogabine—UGT1A3—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	0.000348	0.00231	CbGpPWpGaD
Ezogabine—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000346	0.0017	CcSEcCtD
Ezogabine—UGT1A3—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	0.000343	0.00228	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000343	0.00228	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000343	0.00228	CbGpPWpGaD
Ezogabine—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.00034	0.00167	CcSEcCtD
Ezogabine—UGT1A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000338	0.00224	CbGpPWpGaD
Ezogabine—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000336	0.00165	CcSEcCtD
Ezogabine—KCNQ3—L1CAM interactions—EGFR—chronic obstructive pulmonary disease	0.000334	0.00221	CbGpPWpGaD
Ezogabine—KCNQ2—L1CAM interactions—EGFR—chronic obstructive pulmonary disease	0.000334	0.00221	CbGpPWpGaD
Ezogabine—UGT1A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000333	0.00221	CbGpPWpGaD
Ezogabine—UGT1A1—Phase II conjugation—GSTM1—chronic obstructive pulmonary disease	0.000332	0.0022	CbGpPWpGaD
Ezogabine—UGT1A9—Phase II conjugation—GSTM1—chronic obstructive pulmonary disease	0.000332	0.0022	CbGpPWpGaD
Ezogabine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000329	0.00218	CbGpPWpGaD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	0.000329	0.00218	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000325	0.00216	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000325	0.00216	CbGpPWpGaD
Ezogabine—CYP2A6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000325	0.00215	CbGpPWpGaD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	0.000322	0.00214	CbGpPWpGaD
Ezogabine—UGT1A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.00032	0.00212	CbGpPWpGaD
Ezogabine—UGT1A3—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	0.00032	0.00212	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	0.000319	0.00212	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	0.000319	0.00212	CbGpPWpGaD
Ezogabine—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000317	0.00156	CcSEcCtD
Ezogabine—UGT1A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.000316	0.00209	CbGpPWpGaD
Ezogabine—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000315	0.00155	CcSEcCtD
Ezogabine—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000315	0.00155	CcSEcCtD
Ezogabine—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000313	0.00154	CcSEcCtD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	0.000307	0.00203	CbGpPWpGaD
Ezogabine—UGT1A3—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000305	0.00203	CbGpPWpGaD
Ezogabine—UGT1A1—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000304	0.00202	CbGpPWpGaD
Ezogabine—UGT1A9—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000304	0.00202	CbGpPWpGaD
Ezogabine—UGT1A3—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000301	0.002	CbGpPWpGaD
Ezogabine—UGT1A9—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000301	0.002	CbGpPWpGaD
Ezogabine—UGT1A1—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000301	0.002	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—ADIPOQ—chronic obstructive pulmonary disease	0.000298	0.00198	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—ADIPOQ—chronic obstructive pulmonary disease	0.000298	0.00198	CbGpPWpGaD
Ezogabine—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000295	0.00145	CcSEcCtD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	0.000292	0.00194	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	0.000292	0.00194	CbGpPWpGaD
Ezogabine—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.00029	0.00143	CcSEcCtD
Ezogabine—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000289	0.00142	CcSEcCtD
Ezogabine—CYP2A6—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	0.000289	0.00192	CbGpPWpGaD
Ezogabine—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000282	0.00139	CcSEcCtD
Ezogabine—NAT2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000282	0.00187	CbGpPWpGaD
Ezogabine—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.000281	0.00138	CcSEcCtD
Ezogabine—UGT1A3—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000281	0.00186	CbGpPWpGaD
Ezogabine—Syncope—Prednisone—chronic obstructive pulmonary disease	0.00028	0.00138	CcSEcCtD
Ezogabine—UGT1A3—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000277	0.00184	CbGpPWpGaD
Ezogabine—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000275	0.00135	CcSEcCtD
Ezogabine—NAT2—Metabolism—GC—chronic obstructive pulmonary disease	0.000274	0.00182	CbGpPWpGaD
Ezogabine—CYP2A6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000267	0.00177	CbGpPWpGaD
Ezogabine—UGT1A3—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000266	0.00176	CbGpPWpGaD
Ezogabine—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000265	0.0013	CcSEcCtD
Ezogabine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CTGF—chronic obstructive pulmonary disease	0.000265	0.00176	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000265	0.00175	CbGpPWpGaD
Ezogabine—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000263	0.00129	CcSEcCtD
Ezogabine—UGT1A9—PPARA activates gene expression—CYP1A1—chronic obstructive pulmonary disease	0.000263	0.00174	CbGpPWpGaD
Ezogabine—UGT1A3—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.000262	0.00174	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—APIP—chronic obstructive pulmonary disease	0.000258	0.00171	CbGpPWpGaD
Ezogabine—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CYP1A1—chronic obstructive pulmonary disease	0.000257	0.00171	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000255	0.00169	CbGpPWpGaD
Ezogabine—Infection—Prednisone—chronic obstructive pulmonary disease	0.000254	0.00125	CcSEcCtD
Ezogabine—UGT1A1—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000253	0.00168	CbGpPWpGaD
Ezogabine—UGT1A9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000253	0.00168	CbGpPWpGaD
Ezogabine—Shock—Prednisone—chronic obstructive pulmonary disease	0.000251	0.00123	CcSEcCtD
Ezogabine—CYP2A6—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000251	0.00166	CbGpPWpGaD
Ezogabine—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.00025	0.00123	CcSEcCtD
Ezogabine—UGT1A1—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.00025	0.00165	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.00025	0.00165	CbGpPWpGaD
Ezogabine—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000247	0.00121	CcSEcCtD
Ezogabine—CYP2A6—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	0.000246	0.00163	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	0.000241	0.0016	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	0.000241	0.0016	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	0.000237	0.00157	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	0.000237	0.00157	CbGpPWpGaD
Ezogabine—CYP2A6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000235	0.00156	CbGpPWpGaD
Ezogabine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000232	0.00114	CcSEcCtD
Ezogabine—CYP2A6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000232	0.00154	CbGpPWpGaD
Ezogabine—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000229	0.00113	CcSEcCtD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	0.000227	0.00151	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	0.000227	0.00151	CbGpPWpGaD
Ezogabine—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000225	0.0011	CcSEcCtD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	0.000223	0.00148	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	0.000223	0.00148	CbGpPWpGaD
Ezogabine—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000221	0.00109	CcSEcCtD
Ezogabine—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000221	0.00109	CcSEcCtD
Ezogabine—UGT1A1—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	0.000221	0.00147	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	0.000221	0.00147	CbGpPWpGaD
Ezogabine—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.00022	0.00108	CcSEcCtD
Ezogabine—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000218	0.00107	CcSEcCtD
Ezogabine—UGT1A3—Metabolism—APIP—chronic obstructive pulmonary disease	0.000214	0.00142	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.000214	0.00142	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	0.000212	0.00141	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	0.000212	0.00141	CbGpPWpGaD
Ezogabine—UGT1A1—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000211	0.0014	CbGpPWpGaD
Ezogabine—UGT1A9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000211	0.0014	CbGpPWpGaD
Ezogabine—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.00021	0.00103	CcSEcCtD
Ezogabine—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000209	0.00103	CcSEcCtD
Ezogabine—UGT1A1—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000208	0.00138	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000208	0.00138	CbGpPWpGaD
Ezogabine—CYP2A6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000195	0.00129	CbGpPWpGaD
Ezogabine—UGT1A1—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000194	0.00129	CbGpPWpGaD
Ezogabine—UGT1A9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000194	0.00129	CbGpPWpGaD
Ezogabine—UGT1A1—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000191	0.00127	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000191	0.00127	CbGpPWpGaD
Ezogabine—CYP2A6—Fluoropyrimidine Activity—TP53—chronic obstructive pulmonary disease	0.000188	0.00125	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	0.000185	0.00123	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—LEP—chronic obstructive pulmonary disease	0.000185	0.00123	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—LEP—chronic obstructive pulmonary disease	0.000185	0.00123	CbGpPWpGaD
Ezogabine—UGT1A1—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000184	0.00122	CbGpPWpGaD
Ezogabine—UGT1A9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000184	0.00122	CbGpPWpGaD
Ezogabine—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000183	0.0009	CcSEcCtD
Ezogabine—CYP2A6—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	0.000183	0.00121	CbGpPWpGaD
Ezogabine—UGT1A1—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.000181	0.0012	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.000181	0.0012	CbGpPWpGaD
Ezogabine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000177	0.00118	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000171	0.00113	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	0.00017	0.00113	CbGpPWpGaD
Ezogabine—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000169	0.000829	CcSEcCtD
Ezogabine—UGT1A4—Metabolism—GC—chronic obstructive pulmonary disease	0.000166	0.0011	CbGpPWpGaD
Ezogabine—CYP2A6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000163	0.00108	CbGpPWpGaD
Ezogabine—Rash—Prednisone—chronic obstructive pulmonary disease	0.000161	0.000791	CcSEcCtD
Ezogabine—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000161	0.00079	CcSEcCtD
Ezogabine—UGT1A4—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	0.000157	0.00104	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—MMP9—chronic obstructive pulmonary disease	0.000156	0.00104	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—MMP9—chronic obstructive pulmonary disease	0.000156	0.00104	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000154	0.00102	CbGpPWpGaD
Ezogabine—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000152	0.000745	CcSEcCtD
Ezogabine—NAT2—Metabolism—GSTT1—chronic obstructive pulmonary disease	0.00015	0.000992	CbGpPWpGaD
Ezogabine—CYP2A6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.00015	0.000991	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—GCLC—chronic obstructive pulmonary disease	0.000148	0.000981	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—APIP—chronic obstructive pulmonary disease	0.000148	0.000981	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—APIP—chronic obstructive pulmonary disease	0.000148	0.000981	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000142	0.00094	CbGpPWpGaD
Ezogabine—CYP2A6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000142	0.00094	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—VEGFA—chronic obstructive pulmonary disease	0.00014	0.00093	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—VEGFA—chronic obstructive pulmonary disease	0.00014	0.00093	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GC—chronic obstructive pulmonary disease	0.000138	0.000915	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—CTGF—chronic obstructive pulmonary disease	0.000135	0.000895	CbGpPWpGaD
Ezogabine—UGT1A3—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	0.00013	0.000865	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000128	0.00085	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—EGFR—chronic obstructive pulmonary disease	0.000126	0.000837	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—EGFR—chronic obstructive pulmonary disease	0.000126	0.000837	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000124	0.000825	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—APIP—chronic obstructive pulmonary disease	0.000114	0.000756	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—MMP9—chronic obstructive pulmonary disease	0.000111	0.000739	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—MMP9—chronic obstructive pulmonary disease	0.000111	0.000739	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	0.000105	0.000699	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—GSTP1—chronic obstructive pulmonary disease	0.000104	0.000688	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—HMOX1—chronic obstructive pulmonary disease	0.000102	0.000678	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	0.0001	0.000663	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	0.0001	0.000663	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	9.8e-05	0.00065	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	9.8e-05	0.00065	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	9.72e-05	0.000644	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—IL6—chronic obstructive pulmonary disease	9.7e-05	0.000643	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—IL6—chronic obstructive pulmonary disease	9.7e-05	0.000643	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GC—chronic obstructive pulmonary disease	9.53e-05	0.000632	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GC—chronic obstructive pulmonary disease	9.53e-05	0.000632	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.53e-05	0.000632	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	9.18e-05	0.000609	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	9.18e-05	0.000609	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.07e-05	0.000601	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	9.04e-05	0.000599	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	9.01e-05	0.000598	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	9.01e-05	0.000598	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—EGFR—chronic obstructive pulmonary disease	9e-05	0.000597	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—EGFR—chronic obstructive pulmonary disease	9e-05	0.000597	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—GCLC—chronic obstructive pulmonary disease	8.96e-05	0.000594	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	8.86e-05	0.000588	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	8.86e-05	0.000588	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—TNF—chronic obstructive pulmonary disease	8.58e-05	0.000569	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—TNF—chronic obstructive pulmonary disease	8.58e-05	0.000569	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CTGF—chronic obstructive pulmonary disease	8.18e-05	0.000542	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	7.55e-05	0.000501	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.54e-05	0.0005	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.53e-05	0.0005	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GCLC—chronic obstructive pulmonary disease	7.45e-05	0.000494	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GC—chronic obstructive pulmonary disease	7.35e-05	0.000487	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	7.06e-05	0.000468	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	6.95e-05	0.000461	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—IL6—chronic obstructive pulmonary disease	6.92e-05	0.000459	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—IL6—chronic obstructive pulmonary disease	6.92e-05	0.000459	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	6.83e-05	0.000453	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CTGF—chronic obstructive pulmonary disease	6.8e-05	0.000451	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.28e-05	0.000417	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.26e-05	0.000415	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.2e-05	0.000411	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—ALB—chronic obstructive pulmonary disease	6.14e-05	0.000407	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—NOS3—chronic obstructive pulmonary disease	5.88e-05	0.00039	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.77e-05	0.000383	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.47e-05	0.000363	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.22e-05	0.000346	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.21e-05	0.000345	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.21e-05	0.000345	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.15e-05	0.000342	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GCLC—chronic obstructive pulmonary disease	5.15e-05	0.000341	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GCLC—chronic obstructive pulmonary disease	5.15e-05	0.000341	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.8e-05	0.000318	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	4.8e-05	0.000318	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CTGF—chronic obstructive pulmonary disease	4.7e-05	0.000311	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CTGF—chronic obstructive pulmonary disease	4.7e-05	0.000311	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.55e-05	0.000302	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.33e-05	0.000287	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.33e-05	0.000287	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.01e-05	0.000266	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GCLC—chronic obstructive pulmonary disease	3.97e-05	0.000263	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—ALB—chronic obstructive pulmonary disease	3.72e-05	0.000247	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CTGF—chronic obstructive pulmonary disease	3.62e-05	0.00024	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.61e-05	0.000239	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.61e-05	0.000239	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—NOS3—chronic obstructive pulmonary disease	3.56e-05	0.000236	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.56e-05	0.000236	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.56e-05	0.000236	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.34e-05	0.000221	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.32e-05	0.00022	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.32e-05	0.00022	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.14e-05	0.000208	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.14e-05	0.000208	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—ALB—chronic obstructive pulmonary disease	3.09e-05	0.000205	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—NOS3—chronic obstructive pulmonary disease	2.96e-05	0.000196	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.78e-05	0.000184	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.74e-05	0.000182	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.56e-05	0.00017	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.42e-05	0.000161	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ALB—chronic obstructive pulmonary disease	2.14e-05	0.000142	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ALB—chronic obstructive pulmonary disease	2.14e-05	0.000142	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—NOS3—chronic obstructive pulmonary disease	2.04e-05	0.000136	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—NOS3—chronic obstructive pulmonary disease	2.04e-05	0.000136	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ALB—chronic obstructive pulmonary disease	1.65e-05	0.000109	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—NOS3—chronic obstructive pulmonary disease	1.58e-05	0.000105	CbGpPWpGaD
